While approaches designed to induce ROS have shown considerable promise in selectively targeting cancer cells and dealing with resistance to conventional therapies, most are still in early phases of development and challenges remain. Further research should endeavour to refine treatment strategies, optimize drug combinations, and identify predictive biomarkers of ROS-based cancer therapies.